alcaftadine · Abbvie · NDA 022134
Lastacaft
Earliest generic entry, as listed
23 Dec 2027
Blocked by patent: US 8664215. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8664215 | use U-3267 · sets the listed date | 23 Dec 2027 |
| US 10617695 | drug product, use U-3267 | 19 Mar 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022134 · 001 · RLD | solution/drops, ophthalmic | 0.25% | 23 Dec 2027 |